Unknown

Dataset Information

0

MiR-181b targets semaphorin 3A to mediate TGF-β-induced endothelial-mesenchymal transition related to atrial fibrillation.


ABSTRACT: Atrial fibrosis is an essential contributor to atrial fibrillation (AF). It remains unclear whether atrial endocardial endothelial cells (AEECs) that undergo endothelial-mesenchymal transition (EndMT) are among the sources of atrial fibroblasts. We studied human atria, TGF-β-treated human AEECs, cardiac-specific TGF-β-transgenic mice, and heart failure rabbits to identify the underlying mechanism of EndMT in atrial fibrosis. Using isolated AEECs, we found that miR-181b was induced in TGF-β-treated AEECs, which decreased semaphorin 3A (Sema3A) and increased EndMT markers, and these effects could be reversed by a miR-181b antagomir. Experiments in which Sema3A was increased by a peptide or decreased by a siRNA in AEECs revealed a mechanistic link between Sema3A and LIM-kinase 1/phosphorylated cofilin (LIMK/p-cofilin) signaling and suggested that Sema3A is upstream of LIMK in regulating actin remodeling through p-cofilin. Administration of the miR-181b antagomir or recombinant Sema3A to TGF-β-transgenic mice evoked increased Sema3A, reduced EndMT markers, and significantly decreased atrial fibrosis and AF vulnerability. Our study provides a mechanistic link between the induction of EndMT by TGF-β via miR-181b/Sema3A/LIMK/p-cofilin signaling to atrial fibrosis. Blocking miR-181b and increasing Sema3A are potential strategies for AF therapeutic intervention.

SUBMITTER: Lai YJ 

PROVIDER: S-EPMC9246393 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2022-04-27 | GSE201318 | GEO
2022-04-13 | GSE156835 | GEO
| PRJNA659236 | ENA
| PRJNA830857 | ENA
| S-EPMC7442651 | biostudies-literature
| S-EPMC3949669 | biostudies-literature
| S-EPMC2843238 | biostudies-literature
| S-EPMC3553056 | biostudies-literature
| S-EPMC8252788 | biostudies-literature
| S-EPMC3623806 | biostudies-literature